Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With U… (NCT04398368) | Clinical Trial Compass
TerminatedPhase 2
Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study
Stopped: Focus research efforts on other projects.
United States25 participantsStarted 2020-06-05
Plain-language summary
This phase II trial studies how well gemcitabine works in preventing urothelial cancer from coming back within the bladder (intravesical recurrence) in patients with upper urinary tract urothelial cancer undergoing radical nephroureterectomy. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Instilling gemcitabine into the bladder during surgery, may reduce the chance of recurrence of upper urinary tract urothelial cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinical diagnosis of localized (clinical American Joint Committee on Cancer \[AJCC\] stage Ta-T4N0M0) low- and high-grade UC of the renal pelvis and/or ureter
* Plan to undergo RNU
* Creatinine \< 2.2 mg/dL (194 mmol/L)
* Hemoglobin \> 9 g/dL
* White blood cell count \>= 3000/uL
* Platelet count \> 75,000/uL and \< 500,000/uL
* Serum bilirubin levels below 2 times the institution's upper limits of normal
* Alkaline phosphatase levels below 2 times the institution's upper limits of normal
* Aspartate aminotransferase levels below 2 times the institution's upper limits of normal
* Alanine aminotransferase levels below 2 times the institution's upper limits of normal
* Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2
* Suitable candidate for surgery at the discretion of the investigator
* Patient must be capable of giving appropriate approved informed consent or have an appropriate representative available to do
* Patient with a prior malignancy allowed if adequately treated \> 3 years ago with no current evidence of disease
* Women of childbearing potential (WOCBP) must have a negative pregnancy urine test within 28 days of registration, and be using an adequate method of contraception to avoid pregnancy prior to and for at least 6 months after gemcitabine instillation to minimize the risk of pregnancy
* Male patient who has a partner that is a WOCBP must agree to use physician-approved contraceptive methods (e.g., abstinence, con…